Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
McDowell, Colleen M , Kizhatil, Krishnakumar , Elliott, Michael H. , Overby, Darryl R. , Sherwood, Joseph M. , Millar, J. Cameron , Kuehn, Markus H. , Zode, Gulab , Acott, Ted S. , Anderson, Michael G. , Bertrand, Jacques, Borrás, Terete, Bovenkamp, Diane E. , Cheng, Lin , Danias, John, Ieso, Michael L. De , Du, Yiqin , Faralli, Jennifer A., Fuchshofer, Rudolf , Ganapathy, Preethi S. , Gong, Haiyan , Hernandez, Humberto , John, Simon W. M. , Kaufman, Paul L., Keller, Kate E. , Kelley, Mary J. , Kelly, Ruth A. , Križaj, David , Kumar, Ajay , Leonard, Brian C. , Liu, Katy C., López, Navita N., Mao, Weiming , Mavlyutov, Timur, McDonnell, Fiona , Mzyk, Philip , Nartey, Andrews , Pasquale, Louis R. , Patel, Gaurang , Pattabiraman, Padmanabhan P. , Peters, Donna M. , Raghunathan, Vijaykrishna, Rao, Ponugoti Vasantha , Rayana, Naga Pradeep , Raychaudhuri, Urmimala, Reina‐Torres, Ester , Rhee, Douglas J. , Chowdhury, Uttio Roy, Samples, John R., Samples, E. Griffen, Sharif, Najam A. , Schuman, Joel S. , Stevenson, Cooper H., Soundararajan, Avinash , Subramanian, Preeti, Sugali, Chenna Kesavulu , Sun, Yang , Torrejon, Karen Y., Vahabikashi, Amir , Vranka, Janice A., Wang, Ting , Willoughby, Colin E. , Chen, Xin , Yun, Hongmin , Fautsch, Michael P. , Tamm, Ernst R. , Clark, Abbot F. , Ethier, C. Ross , Schuman, Joel S , Bhattacharya, Sanjoy K. , Bertrand, Jacques A., Herberg, Samuel , Humphries, Peter , Lieberman, Raquel L. , Liton, Paloma B. , Liu, Yutao , McLellan, Gillian J. , Raghunathan, Vijay Krishna , Rao, Ponugoti Vasantha , Ren, Ruiyi , Sheffield, Val C. , Toris, Carol B. , Zhang, Hao F. , Stamer, William Daniel

Mayo Clinic

Investigative Opthalmology & Visual Science | February 7, 2022 | Volume: 63 | Issue: 2 | Pages: 12

10.1167/iovs.63.2.12 | PMID 35129590 Get It

The COX-2–PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas
Wei, Jie, Zhang, Jinyu, Wang, Dingzhi, Cen, Bo, Lang, Jessica D. , DuBois, Raymond N., Wei, Jie, Zhang, Jinyu, Wang, Dingzhi, Cen, Bo, Lang, Jessica D. , DuBois, Raymond N.

Mayo Clinic

Cancer Prevention Research | February 4, 2022 | Volume: 15 | Issue: 5 | Pages: 285-296

10.1158/1940-6207.capr-21-0572 | PMID 35121582 Get It

Abstract The mechanisms underlying the regulation of a checkpoint receptor, PD-1, in tumor-infiltrating immune cells during the development of colorectal cancer are not fully understood. Here we demonstrate that COX-2–derived PGE2, an inflammatory mediator and tumor promoter, induces PD-1 expression by enhancing NFκB's binding to the PD-1 promoter via an EP4–PI3K–Akt signaling pathway in both CD8+ T cells and macrophages. Moreover, PGE2 suppresses CD8+ T-cell proliferation and cytotoxicity against tumor cells and impairs macrophage phagocytosis of cancer cells via an EP4–PI3K–Akt–NFκB–PD-1 signaling pathway. In contrast, inhibiting the COX-2–PGE2–EP4 pathway increases intestinal CD8+ T-cell activation and proliferation and enhances intestinal macrophage phagocytosis of carcinoma cells accompanied by reduction of PD-1 expression in intestinal CD8+ T cells and macrophages in ApcMin/+ mice. PD-1 expression correlates well with COX-2 levels in human colorectal cancer specimens. Both elevated PD-1 and COX-2 are associated with poorer overall survival in patients with colorectal cancer. Our results uncover a novel role of PGE2 in tumor immune evasion. They may provide the rationale for developing new therapeutic approaches to subvert this process by targeting immune checkpoint pathways using EP4 antagonists. In addition, our findings reveal a novel mechanism explaining how NSAIDs reduce colorectal cancer risk by suppressing tumor immune evasion. Prevention Relevance: These findings provide a potential explanation underlying the chemopreventive effect of NSAIDs on reducing colorectal cancer incidence during premalignancy and provide a rationale for developing EP4 antagonists for colorectal cancer prevention and treatment. Simply targeting PGE2 signaling alone may be efficacious in colorectal cancer prevention and treatment, avoiding side effects associated with NSAIDs.
The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma
Khalafallah, Adham M. , Rakovec, Maureen , Burapachaisri, Katemanee , Fung, Shirley , Kozachik, Sharon , Valappil, Benita, Abou‐Al‐Shaar, Hussam , Zenonos, Georgios A. , Gardner, Paul A. , Başkaya, Mustafa K. , Dornbos, David , Roxbury, Christopher R. , Overdevest, Jonathan B. , Lee, Victoria S. , Levy, Joshua M. , Thamboo, Andrew , Schlosser, Rodney J. , London, Nyall R. , Wu, Albert W., Mukherjee, Debraj , Levy, Joshua M , Schlosser, Rodney J , Mukherjee, Debraj , Wang, Eric W , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Gudis, David A. , Huang, Judy , Bettegowda, Chetan , Rowan, Nicholas R.

Mayo Clinic

Journal of Neurosurgery | February 2, 2022 | Volume: 136 | Issue: 6 | Pages: 1551-1559

10.3171/2021.6.jns21517 | PMID 34874673 Get It

OBJECTIVE Suprasellar meningioma resection via either the transcranial approach (TCA) or the endoscopic endonasal approach (EEA) is an area of controversy and active evaluation. Skull base surgeons increasingly consider patient-reported outcomes (PROs) when choosing an approach. No PRO measure currently exists to assess quality of life for suprasellar meningiomas. METHODS Adult patients undergoing suprasellar meningioma resection between 2013 and 2019 via EEA (n = 14) or TCA (n = 14) underwent semistructured interviews. Transcripts were coded using a grounded theory approach to identify themes as the basis for a PRO measure that includes all uniquely reported symptoms. To assess content validity, 32 patients and 15 surgeons used a Likert scale to rate the relevance of items on the resulting questionnaire and the general Patient-Reported Outcomes Measurement Information System–29 (PROMIS29). The mean scores were calculated for all items and compared for TCA versus EEA patient cohorts by using unpaired t-tests. Items on either questionnaire with mean scores ≥ 2.0 from patients were considered meaningful and were aggregated to form the novel Suprasellar Meningioma Patient-Reported Outcome Survey (SMPRO) instrument. RESULTS Qualitative analyses resulted in 55 candidate items. Relative to patients who underwent the EEA, those who underwent the TCA reported significantly worse future outlook before surgery (p = 0.01), tiredness from medications 2 weeks after surgery (p = 0.001), and word-finding and memory difficulties 3 months after surgery (p = 0.05 and < 0.001, respectively). The items that patients who received a TCA were most concerned about included medication-induced lethargy after surgery (2.9 ± 1.3), blurry vision before surgery (2.7 ± 1.5), and difficulty reading due to blurry vision before surgery (2.7 ± 2.7). Items that patients who received an EEA were most concerned about included blurry vision before surgery (3.5 ± 1.3), difficulty reading due to blurry vision before surgery (2.4 ± 1.3), and problems with smell postsurgery (2.9 ± 1.3). Although surgeons overall overestimated how concerned patients were about questionnaire items (p < 0.0005), the greatest discrepancies between patient and surgeon relevance scores were for blurry vision pre- and postoperatively (p < 0.001 and < 0.001, respectively) and problems with taste postoperatively (p < 0.001). Seventeen meningioma-specific items were considered meaningful, supplementing 8 significant PROMIS29 items to create the novel 25-item SMPRO. CONCLUSIONS The authors developed a disease- and approach-specific measure for suprasellar meningiomas to compare quality of life by operative approach. If demonstrated to be reliable and valid in future studies, this instrument may assist patients and providers in choosing a personalized surgical approach.
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Peddi, Parvin F., Fasching, Peter A. , Liu, Duan , Quinaux, Emmanuel, Robert, Nicholas J., Valero, Vicente, Falkson, Carla I. , Brufsky, Adam , Cunningham, Julie M. , Weinshilboum, Richard M., Pienkowski, Tadeusz, Eiermann, Wolfgang, Bee, Valerie, Wang, Xiaoyan, Wang, Liewei, Yang, Eric H. , Slamon, Dennis J., Hurvitz, Sara A., Pieńkowski, Tadeusz , Crown, John , Falkson, Carla , Brufsky, Adam M , Cunningham, Julie M , Martin, Miguel , Yang, Eric , Liu, Duan , Peddi, Parvin F., Fasching, Peter A , Quinaux, Emmanuel, Robert, Nicholas J., Valero, Vicente, Weinshilboum, Richard M., Eiermann, Wolfgang, Bee, Valerie, Wang, Xiaoyan, Wang, Liewei, Slamon, Dennis J., Hurvitz, Sara A.

Mayo Clinic

Clinical Cancer Research | February 2, 2022 | Volume: 28 | Issue: 9 | Pages: 1854-1862

10.1158/1078-0432.ccr-21-1762 | PMID 35110416 Get It

Abstract Purpose: Cardiac toxicity is a serious potential complication of HER2-directed therapies and anthracyclines. HER2 codon 655 and SLC28A3 gene polymorphisms have been reported to be associated with cardiac toxicity from anti-HER2 and anthracycline therapy, respectively. Association of the polymorphism at HER2 codon 655 with prognosis has also been reported. Experimental Design: Whole blood samples from patients treated on a randomized adjuvant breast cancer trial (BCIRG-006) that compared chemotherapy with or without trastuzumab plus either anthracycline or nonanthracycline chemotherapy were tested for genetic polymorphisms in HER2 codon 655 and SLC28A3. Genotypes were correlated with cardiac function and disease-free survival (DFS) outcomes. Results: Of 3,222 patients enrolled in BCIRG-006, 662 patient samples were successfully genotyped for the rs1136201 allele in HER2 (codon 655): 424 (64%) were AA, 30 (4.5%) were GG, and 208 (31%) were AG genotype. In addition, 665 patient samples were successfully genotyped for the rs7853758 allele in the SLC28A3 gene: 19 (3%) were AA, 475 (71%) were GG, and 171 (26%) were AG genotype. Follow-up time was 10 years. No correlation between DFS, cardiac event rate, or mean left ventricular ejection fraction (LVEF) and rs1136201 genotype was seen in the trastuzumab-treated or non–trastuzumab-treated patients. Moreover, mean LVEF and cardiac event rates were similar in all rs7853758 genotype groups treated with anthracycline-based therapy. Conclusions: In the largest study to date to evaluate whether two polymorphisms are associated with DFS and/or cardiac toxicity in HER2-positive breast cancer treated with trastuzumab and/or anthracyclines, we observed no correlation.
Identifying precision AD biomarkers with varying prognosis effects in genetics driven subpopulations
Lee, Brian N. , Wang, Junwen , Wang, Junwen , Shen, Li

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.053201 Get It

AbstractBackgroundImaging, cognitive and fluid data have been widely studied to identify quantitative biomarkers that can help predict the status and progression of Alzheimer’s disease (AD). However, it is still an underexplored topic whether there exist subpopulations with different genetic profiles across which the biomarker‐based prediction models may vary. We propose to use the Chow test (Chow 1960 Econometrica 28(3)) to perform genetically stratified analyses for identifying SNP‐based subpopulations coupled with precision AD biomarkers with varying effects on future diagnosis in these subpopulations. The investigation of such SNPs and precision biomarkers may eventually pave the way for increased customization of AD care.MethodParticipants included 1,324 subjects from the ADNI cohort with both AD biomarker and genotyping data available (http://www.pi4cs.org/qt‐pad‐challenge). 30 significant (P < 1.5E‐278) AD SNPs were sourced from (Jansen 2019 NatGen). Chow tests were performed to determine whether each of baseline visit measures of 16 AD biomarkers predicted AD diagnosis at the three‐year visit with varying slopes when stratifying upon the allelic dosage of each of 30 chosen SNPs. Bonferroni correction (P < 1.04E‐4) was employed to correct for multiple comparisons.ResultMultiple SNP‐biomarker pairs showed significant genetically driven deviations in the regression coefficients when predicting diagnosis in three years using baseline biomarkers (Figure 1). Top SNP hits involved rs769449 (Chr 19, APOE) and rs7561528 (Chr 2, LOC105373605), and almost all 16 studied biomarkers demonstrated differential slopes in different genotype groups to predict diagnosis in three years. To examine the details of these top findings, the regression coefficients calculated for each of the five most significant biomarkers of both SNPs were bootstrapped and plotted in Figure 2.ConclusionGenetic analysis of AD candidate SNPs in conjunction with AD biomarker data via the Chow test identified several SNPs coupled with precision AD biomarkers with varying prognosis effects in the corresponding genotype groups. These findings provide valuable information to reveal disease heterogeneity and help facilitate precision medicine.
Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease
Barthélemy, Nicolas R. , Goate, Alison , Hassenstab, Jason , Fagan, Anne M. , Xiong, Chengjie , Cruchaga, Carlos , Farlow, Martin R. , Graff‐Radford, Neill R. , Laske, Christoph , Masters, Colin L. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Chhatwal, Jasmeer P. , Fitzpatrick, Colleen , Bodge, Courtney, Cruz, Chrismary De La, Mejia, Arlene, Neimeyer, Katie, Gardener, Samantha L. , Taddei, Kevin , Ping, Lingyan, Seyfried, Nick , Gräber‐Sultan, Susanne, Häsler, Lisa M., Käser, Stephan, Kuder-Buletta, Elke, Preische, Oliver, Diffenbacher, Anna, Igor, Yakushev, Levin, Johannes, Vöglein, Jonathan , Obermüller, Ulricke, Esposito, Bianca, Goate, Alison, Buck, Jill , Farlow, Marty, Chrem, Patricio, Egido, Noelia , Haass, Christian , Nuscher, Brigitte , Day, Gregory S. , Graham, Morgan, Stephens, Sochenda, Bechara, Jacob , Araki, Aki, Ishii, Kenji , Senda, Michio , Ihara, Ryoko , Nagamatsu, Akemi, Fox, Nick C. , Mummery, Cath, Goldberg, Sarah B. , Ikonomović, Snežana, Mountz, James M. , Nadkarni, Neelesh K. , Patira, Riddhi , Smith, Lori, Snitz, Beth E. , Thompson, Sarah , Weamer, Elise A., Mason, Neal Scott, Chui, Helena, Ringman, John M. , Adams, Sarah , Brandon, Susan E. , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chua, Jasmin, Cruchaga, Carlos, Denner, Darcy, Dincer, Aylin , Donahue, Tamara, Feldman, Becca , Franklin, Erin , Friedrichsen, Nelly, Gonzalez, Alyssa, Gray, Julia, Gremminger, Emily, Groves, Alex, Hassenstab, Jason, Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Jerome, Gina, Keefe, Sarah , Koudelis, Deb, Martinez, Rita, Mawuenyega, Kwasi G., McCullough, Austin , McDade, Eric, Norton, Joanne, Perrin, Richard J. , Shady, Kristine, Sigurdson, Wendy, Xu, Jinbin , Cruchaga, Carlos , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Lim, Yen Ying , Maruff, Paul , Sato, Chihiro , Benzinger, Tammie L.S. , Xiong, Chengjie , Schofield, Peter R. , McDade, Eric , Network, Dominantly Inherited Alzheimer, Fitzpatrick, Colleen, Goldman, Jill , Noble, James M. , Martins, Ralph N. , Sohrabi, Hamid R. , Carter, Kathleen, Duong, Duc M , Johnson, Erik C. B. , Levey, Allan I. , Ping, Lingyan, Hofmann, Anna, Jucker, Mathias , Levin, Johannes, Goate, Alison, Renton, Alan , Brosch, Jared R. , Buck, Jill, Ghetti, Bernardino , Allegri, Ricardo , Morenas‐Rodríguez, Estrella , Jack, Clifford R. , Brooks, William S. , Ikeuchi, Takeshi , Kasuga, Kensaku , Fujii, Hisako , Shimada, Hiroyuki , Niimi, Yoshiki , Douglas, Jane, Grilo, Miguel, O’Connor, Antoinette , Koeppe, Robert A. , Berman, Sarah , Klunk, William E. , López, Oscar L. , Brandon, Susan, Cruchaga, Carlos, Feldman, Becca, Flores, Shaney , Gordon, Brian A. , Hassenstab, Jason, Holtzman, David M. , Karch, Celeste M. , Li, Yan , Marsh, Jacob, McDade, Eric, Smith, Jennifer A. , Wang, Peter , Wang, Qing , Xu, Xiong

Mayo Clinic

JAMA Neurology | January 31, 2022 | Volume: 79 | Issue: 3 | Pages: 261

10.1001/jamaneurol.2021.5181 | PMID 35099506 Get It

Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration
Rivard, Léna , Friberg, Leif , Conen, David , Healey, Jeff S. , Berge, Trygve , Boriani, Giuseppe , Brandes, Axel , Calkins, Hugh , Camm, A. John , Espuny, Josep Lluis Clua , Collins, Ronan, Connolly, Stuart, Dagres, Nikolaos , Elkind, Mitchell S.V. , Engdahl, Johan, Field, Thalia S. , Glotzer, Taya V., Hankey, Graeme J. , Hills, Mellanie True , Johnson, Linda S.B. , Joung, Boyoung, Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Montaner, Joan , Rienstra, Michiel , Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Stavrakis, Stavros , Gelder, Isabelle C. Van, Wang, Ji‐Guang , Freedman, Ben , Joung, Boyoung , Healey, Jeffrey S , Chen, Lin Y , Lluis Clua Espuny, Josep , Dagres, Nikolaos , Elkind, Mitchell S V , Field, Thalia S , Gersh, Bernard J , Hankey, Graeme J , Harbison, Joseph A , Haeusler, Karl G , True Hills, Mellanie , Johnson, Linda S B , Khairy, Paul , Kirchhof, Paulus , Lip, Gregory Y H , Montaner, Joan , Ntaios, George , Quinn, Terence J , Rienstra, Michiel , Schnabel, Renate B , Stavrakis, Stavros , Themistoclakis, Sakis , Wang, Ji-Guang , Freedman, Ben , Boriani, Giuseppe , Joung, Boyoung , Brandes, Axel , Rivard, Lena , Friberg, Leif , Conen, David , Berge, Trygve , Calkins, Hugh , Camm, Alan John , Collins, Ronan, Connolly, Stuart, Engdahl, Johan, Glotzer, Taya V., Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Gelder, Isabelle C. Van

Mayo Clinic

Circulation | January 31, 2022 | Volume: 145 | Issue: 5 | Pages: 392-409

10.1161/circulationaha.121.055018 | PMID 35100023 Get It

Growing evidence suggests a consistent association between atrial fibrillation (AF) and cognitive impairment and dementia that is independent of clinical stroke. This report from the AF-SCREEN International Collaboration summarizes the evidence linking AF to cognitive impairment and dementia. It provides guidance on the investigation and management of dementia in patients with AF on the basis of best available evidence. The document also addresses suspected pathophysiologic mechanisms and identifies knowledge gaps for future research. Whereas AF and dementia share numerous risk factors, the association appears to be independent of these variables. Nevertheless, the evidence remains inconclusive regarding a direct causal effect. Several pathophysiologic mechanisms have been proposed, some of which are potentially amenable to early intervention, including cerebral microinfarction, AF-related cerebral hypoperfusion, inflammation, microhemorrhage, brain atrophy, and systemic atherosclerotic vascular disease. The mitigating role of oral anticoagulation in specific subgroups (eg, low stroke risk, short duration or silent AF, after successful AF ablation, or atrial cardiopathy) and the effect of rhythm versus rate control strategies remain unknown. Likewise, screening for AF (in cognitively normal or cognitively impaired patients) and screening for cognitive impairment in patients with AF are debated. The pathophysiology of dementia and therapeutic strategies to reduce cognitive impairment warrant further investigation in individuals with AF. Cognition should be evaluated in future AF studies and integrated with patient-specific outcome priorities and patient preferences. Further large-scale prospective studies and randomized trials are needed to establish whether AF is a risk factor for cognitive impairment, to investigate strategies to prevent dementia, and to determine whether screening for unknown AF followed by targeted therapy might prevent or reduce cognitive impairment and dementia.
High-impact chronic pain transition in surgical recipients with cervical spondylotic myelopathy
Cook, Chad E., George, Steven Z., Asher, Anthony L., Bisson, Erica F., Buchholz, Avery L., Bydon, Mohamad, Chan, Andrew K., Haid, Regis W., Mummaneni, Praveen V., Park, Paul, Shaffrey, Christopher I., Than, Khoi D., Tumialan, Luis M., Wang, Michael Y., Gottfried, Oren N., Park, Paul , Cook, Chad E., George, Steven Z., Asher, Anthony L., Bisson, Erica F., Buchholz, Avery L., Bydon, Mohamad, Chan, Andrew K., Haid, Regis W., Mummaneni, Praveen V., Park, Paul, Shaffrey, Christopher I., Than, Khoi D., Tumialan, Luis M., Wang, Michael Y., Gottfried, Oren N.

Mayo Clinic

Journal of Neurosurgery: Spine | January 28, 2022 | Volume: 37 | Issue: 1 | Pages: 31-40

10.3171/2021.11.spine211260 | PMID 35061992 Get It

OBJECTIVE High-impact chronic pain (HICP) is a recently proposed metric that indicates the presence of a severe and troubling pain-related condition. Surgery for cervical spondylotic myelopathy (CSM) is designed to halt disease transition independent of chronic pain status. To date, the prevalence of HICP in individuals with CSM and their HICP transition from presurgery is unexplored. The authors sought to define HICP prevalence, transition, and outcomes in patients with CSM who underwent surgery and identify predictors of these HICP transition groups. METHODS CSM surgical recipients were categorized as HICP at presurgery and 3 months if they exhibited pain that lasted 6–12 months or longer with at least one major activity restriction. HICP transition groups were categorized and evaluated for outcomes. Multivariate multinomial modeling was used to predict HICP transition categorization. RESULTS A majority (56.1%) of individuals exhibited HICP preoperatively; this value declined to 15.9% at 3 months (71.6% reduction). The presence of HICP was also reflective of other self-reported outcomes at 3 and 12 months, as most demonstrated notable improvement. Higher severity in all categories of self-reported outcomes was related to a continued HICP condition at 3 months. Both social and biological factors predicted HICP translation, with social factors being predominant in transitioning to HICP (from none preoperatively). CONCLUSIONS Many individuals who received CSM surgery changed HICP status at 3 months. In a surgical population where decisions are based on disease progression, most of the changed status went from HICP preoperatively to none at 3 months. Both social and biological risk factors predicted HICP transition assignment.